Homocysteine and cognitive function in Parkinson's disease.
Homocysteine and cognitive function in Parkinson's disease.
复制标题
DOI:
10.1016/j.parkreldis.2017.08.005
复制
发表时间:
2017-11
影响因子:
4.1
通讯作者:
Quinn JF
中科院分区:
文献类型:
--
作者:
Licking N;Murchison C;Cholerton B;Zabetian CP;Hu SC;Montine TJ;Peterson-Hiller AL;Chung KA;Edwards K;Leverenz JB;Quinn JF
Increased plasma homocysteine (HC) is a risk factor for dementia in the general population. Levodopa therapy causes increased plasma HC, but it remains unclear whether elevated plasma HC is associated with cognitive impairment in Parkinson’s disease (PD). The study population includes all participants in the Pacific Northwest Udall Center (PANUC) Clinical cohort at the time of the study, consisting of 294 individuals with PD who had a standardized neuropsychological assessment and plasma collection for HC measurement. We tested the hypothesis that elevated plasma HC is inversely related to cognitive function in patients with PD. As expected, plasma HC was positively associated with age, disease duration, disease severity, and levodopa usage, while cognitive function was associated with age, education, gender, and APOE genotype, so subsequent analyses controlled for these covariates. When plasma HC was dichotomized as normal (<14 μmol/L) or elevated (≥14 μmol/L), subjects with hyper-homocysteinemia had lower scores on Digit Symbol (p=0.031), Hopkins Verbal Learning Task (HVLT) Delayed Recall (p=0.004), and semantic verbal fluency (p=0.049). When examined as a continuous variable, plasma HC was inversely associated with HVLT Delayed Recall (p=0.009)) and semantic verbal fluency (p=0.004), but was not significantly related to Digit symbol, Trail-making test, Judgment of Line Orientation, phonemic verbal fluency, MMSE, or MOCA. When analysis was restricted to non-demented subjects (n=231), the findings were unchanged. We conclude that plasma HC is significantly associated with some aspects of cognitive function in PD, and may represent a treatable risk factor for cognitive decline in PD.
登录
查看更多内容
DOI:
10.3233/jpd-130189
发表时间:
2013
期刊:
Journal of Parkinson's disease
影响因子:
--
作者:
Cholerton BA;Zabetian CP;Quinn JF;Chung KA;Peterson A;Espay AJ;Revilla FJ;Devoto J;Watson GS;Hu SC;Edwards KL;Montine TJ;Leverenz JB
通讯作者:
Leverenz JB
影响因子:
8.6
作者:
Goldman, Jennifer G.;Holden, Samantha;Ouyang, Bichun;Bernard, Bryan;Goetz, Christopher G.;Stebbins, Glenn T.
通讯作者:
Stebbins, Glenn T.
DOI:
10.1002/mds.26359
发表时间:
2016-01
期刊:
Movement disorders : official journal of the Movement Disorder Society
影响因子:
--
作者:
Mata IF;Leverenz JB;Weintraub D;Trojanowski JQ;Chen-Plotkin A;Van Deerlin VM;Ritz B;Rausch R;Factor SA;Wood-Siverio C;Quinn JF;Chung KA;Peterson-Hiller AL;Goldman JG;Stebbins GT;Bernard B;Espay AJ;Revilla FJ;Devoto J;Rosenthal LS;Dawson TM;Albert MS;Tsuang D;Huston H;Yearout D;Hu SC;Cholerton BA;Montine TJ;Edwards KL;Zabetian CP
通讯作者:
Zabetian CP
影响因子:
4
作者:
Song, In-Uk;Kim, Joong-Seok;Lee, Kwang-Soo
通讯作者:
Lee, Kwang-Soo
影响因子:
29
作者:
Mata, Ignacio F.;Leverenz, James B.;Weintraub, Daniel;Trojanowski, John Q.;Hurtig, Howard I.;Van Deerlin, Vivianna M.;Ritz, Beate;Rausch, Rebecca;Rhodes, Shannon L.;Factor, Stewart A.;Wood-Siverio, Cathy;Quinn, Joseph F.;Chung, Kathryn A.;Peterson, Amie L.;Espay, Alberto J.;Revilla, Fredy J.;Devoto, Johnna;Hu, Shu-Ching;Cholerton, Brenna A.;Wan, Jia Y.;Montine, Thomas J.;Edwards, Karen L.;Zabetian, Cyrus P.
通讯作者:
Zabetian, Cyrus P.